TIMER
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
The primary endpoint of the study is the evolution of walking abilities as measured by MWD, EDSS, T25FW and T100T during the first year of therapy with natalizumab.
Disability progressionWalking and mobility
Who could take part
Relapsing MS
Inclusion: 1. Must give written informed consent and provide all authorizations required by local law (e.g., Protected Health Information [PHI]) Exclusion: Medical History:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the evolution of walking capacity as measured by T100T, T25FW, MWD and EDSS during the first year of therapy with natalizumab
Loading reviews and guidelines…
Related trials
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumar…
Recruiting
Still running
- A Study Utilising Data From European Union (EU) National …
Running, not recruiting
Still running
- SATURATE-MS
Stopped early
Stopped early
- A Study to Investigate the Radiological Onset of Action A…
Phase 4 · Stopped early
Stopped early
- The 'Wearing Off' Effect of DMT
Completed
No result found
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, a…
Phase 3 · Stopped early
Stopped: not working
History
Started
May 2009
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error